Non-Small Cell Lung Cancer

Featured

News
Higher out-of-pocket costs for TKIs are associated with decreased therapy adherence among patients with EGFR- and ALK-positive NSCLC.
Quiz
True or False: Higher out-of-pocket costs for TKIs among patients with EGFR- and ALK-positive advanced NSCLC are…
News
Study findings show TKI therapy, immunotherapy, and chemotherapy are relatively small drivers of unplanned acute…
FDA Approval
The FDA granted approval to osimertinib as adjuvant therapy after tumor resection for patients with NSCLC and EGFR…
News
Study results show timely specialty palliative care for patients with metastatic NSCLC is associated with lower health…